Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases
- 1 February 2018
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 45 (2), 202-206
- https://doi.org/10.1111/1346-8138.14114
Abstract
Pityriasis rubra pilaris (PRP) is a rare, chronic, inflammatory skin disease of unknown etiology. Patients refractory to conventional therapies have been treated successfully with biologic drugs such as anti-tumor necrosis factor agents. Recently, a role of the interleukin-23/T-helper 17 axis in PRP has been described. Our objective was to assess the effectiveness of ustekinumab in five patients with adult-onset PRP refractory to conventional therapies. In the present study, four patients had type I and one patient type II adult-onset PRP. They were treated with three s.c. doses of ustekinumab at weeks 0, 4 and 16. Clinical response was evaluated monthly during treatment up to a 15-month follow-up period. All patients promptly showed a decrease in erythema, follicular hyperkeratosis and scaling. After three injections, complete remission of skin lesions was achieved in four out of five cases and a significant clinical improvement was shown in one case. To the best of our knowledge, this is the largest case series reported on ustekinumab treatment in PRP. Our results, in addition to previous studies from other groups, suggest that ustekinumab may be a possible first-line treatment for PRP patients refractory to conventional therapies.Keywords
Funding Information
- Ministero della Salute
This publication has 15 references indexed in Scilit:
- Ustekinumab as an Alternative Treatment Option for Chronic Pityriasis Rubra PilarisCase Reports in Dermatology, 2015
- Ineffectiveness of tumor necrosis factor-α blockers and ustekinumab in a case of type IV pityriasis rubra pilarisIndian Dermatology Online Journal, 2015
- Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation inCARD14British Journal of Dermatology, 2014
- Treatment Options for Pityriasis Rubra Pilaris Including Biologic AgentsJAMA Dermatology, 2014
- Long-term ustekinumab treatment for refractory type I pityriasis rubra pilarisJournal of Dermatological Case Reports, 2013
- A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonistsJournal of the European Academy of Dermatology and Venereology, 2012
- Treatment of refractory adult‐onset pityriasis rubra pilaris with TNF‐alpha antagonists: a case seriesJournal of the European Academy of Dermatology and Venereology, 2010
- Treatment of pityriasis rubra pilaris with ustekinumabBritish Journal of Dermatology, 2010
- Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapyJournal of the American Academy of Dermatology, 2008
- Pityriasis rubra pilaris*Clinical and Experimental Dermatology, 1980